% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gasparin:302846,
author = {F. Gasparin and M. R. Tietje and E. Katab and A. Nurdinova
and T. Yuan and A. Chmyrov and N. Uluç and D. Jüstel and
F. Bassermann$^*$ and V. Ntziachristos and M. A. Pleitez},
title = {{L}abel-free protein-structure-sensitive live-cell
microscopy for patient-specific assessment of myeloma
therapy.},
journal = {Nature biomedical engineering},
volume = {nn},
issn = {2157-846X},
address = {Tokyo},
publisher = {Nature Research},
reportid = {DKFZ-2025-01386},
pages = {nn},
year = {2025},
note = {epub},
abstract = {The efficacy of drug therapy in multiple myeloma is
conventionally assessed by whole-cell-population methods,
serum analysis of light chains and monoclonal antibodies,
immunofixation electrophoresis, or by flow cytometry of bone
marrow aspirates and biopsies. These methods provide
relevant information on the presence of specific
immunoglobulins at high sensitivity and specificity but
require a large number of cells, involve long and laborious
sample preparation steps, and provide only tumour bulk
information. Here we develop a single-cell imaging technique
requiring a reduced number of primary cells for longitudinal
evaluation of patient-specific treatment and assessment of
treatment heterogeneity. By exploiting the mechanistic
action of proteasome inhibition and in synergy with the
label-free protein-structure specificity of mid-infrared
optoacoustic microscopy, we present a technology that
facilitates longitudinal evaluation of myeloma treatment and
a patient's heterogeneous response. Detecting
optical-generated ultrasound waves that intensify with
optical absorption, this technology allows observation of
proteins in living cells with high sensitivity.
Specifically, we use intermolecular β-sheet formation as a
biomarker for cell viability during therapy and apply it to
assess drug-treatment performance in multiple myeloma
patients.},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40659832},
doi = {10.1038/s41551-025-01443-3},
url = {https://inrepo02.dkfz.de/record/302846},
}